Silk Road Medical Inc

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Silk Road Medical Inc reports robust Q4 performance and eyes global expansion

Silk Road Medical Inc's Q4 2022 performance reflects strong revenue growth and operational efficiency, supported by a focus on market expansion and cost management.
While facing challenges in cost control and operational metrics, the company's strategic initiatives and revenue guidance for 2023 signal growth potential.
Opportunities lie in leveraging the cash balance for growth, expanding TCAR utilization, and addressing analyst concerns to drive future success.

Silk Road Medical reports robust Q1 earnings and eyes international expansion

Silk Road Medical's Q1 2023 earnings call highlighted strong revenue growth, innovative product launches, and strategic international expansion plans.
While the company faces challenges in scaling operations and managing costs, it remains well-positioned with a solid financial foundation and a focus on driving sustainable growth.
With a clear focus on optimizing revenue per procedure and expanding geographically, Silk Road Medical is poised to capitalize on opportunities for market growth and product adoption.

Silk Road Medical Inc posts strong Q2 earnings, eyes global expansion

Silk Road Medical Inc delivered robust Q2 2023 results, showcasing revenue growth, product advancements, and strategic progress. While facing competition and regulatory challenges, the company is well-positioned to capitalize on international markets and drive further growth through operational efficiency.

Silk Road Medical posts strong Q3 results, eyes growth opportunities

Silk Road Medical's Q3 2023 earnings call highlighted robust financial performance, leadership changes, strategic initiatives, and market opportunities. The company faces challenges in sales force management and margin optimization but is well-positioned to capitalize on growth prospects.

Silk Road Medical reports robust 2023 earnings, eyes international expansion

Silk Road Medical's strong financial performance in 2023, driven by revenue growth and strategic initiatives, sets the stage for continued success.
While facing challenges such as sales force turnover and market dynamics, the company's focus on innovation and international expansion presents opportunities for growth.
Maintaining a stable pricing strategy, deepening physician adoption, and leveraging new product advancements are key to Silk Road's sustainable growth strategy.
Navigating competition in carotid treatments and maximizing the adoption curve for TCAR procedures are critical areas for Silk Road's future success.

Silk Road Medical reports robust Q1 earnings and eyes international growth

Silk Road Medical's Q1 2024 performance reflects revenue growth, improved EBITDA, and strong financial stability despite operational challenges.
The company's strengths lie in its leadership in carotid treatment, growth opportunities in international markets, and innovative product development.
Challenges include profitability concerns, margin pressure, and the need for efficient cost management amid rising expenses.
Opportunities for Silk Road Medical include market expansion, revenue growth, and continued innovation to solidify its position as a leader in carotid treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Boston Scientific

MARLBOROUGH, Mass. , Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period.

Boston Scientific Announces Results for Third Quarter 2024

MARLBOROUGH, Mass. , Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).

Boston Scientific Closes Acquisition of Silk Road Medical, Inc.

Bally's

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Bally's Corporation (NYSE:BALY)'s sale to Standard General L.P. for $18.25 per share.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY and SILK on Behalf of Shareholders

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. ( N asdaq : SILK ) , relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub. Under the terms of the agreement, Silk Road stockholders will receive $27.50 in cash for each share they own.

SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silk Road Medical, Inc. (NasdaqGS: SILK) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Silk Road will receive $27.50 in cash for each share of Silk Road that they own. KSF is seeking to determine whether this consideration and the process that led to.

SILK ROAD MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silk Road Medical, Inc. - SILK

MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (Nasdaq: SILK) (“SILK”) to Boston Scientific Corporation for $27.50 per share in cash.

SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific

Silk Road Medical (SILK) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.35 per share a year ago.

Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates

Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes through minimally invasive techniques

Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures

NEW YORK , July 29, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK ), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub.

SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger of Silk Road Medical, Inc.

MARLBOROUGH, Mass. , July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period.

Boston Scientific Announces Results for Second Quarter 2024

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. ( N asdaq : SILK ) , relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub. Under the terms of the agreement, Silk Road stockholders will receive $27.50 in cash for each share they own.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. – SILK

NEW YORK , July 15, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK ), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. - SILK

MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $27.50 per share in cash for which Silk Road Medical, Inc. (Nasdaq: SILK) (“SILK”) has agreed to be sold to Boston Scientific Corporation (“Boston Scientific”).

SILK Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Silk Road Medical to Boston Scientific

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Silk Road Medical (SILK): Can Its 24.0% Jump Turn into More Strength?

NEW YORK , June 18, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Silk Road Medical, Inc. (NASDAQ: SILK) and its board of directors concerning the proposed acquisition of the company by Boston Scientific Corporation (NYSE: BSX). Stockholders will receive $27.50 for each share of Silk Road Medical stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Silk Road Medical, Inc.

MILWAUKEE , June 18, 2024 /PRNewswire/ -- Ademi LLP is investigating Silk Road Medical (Nasdaq: SILK) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific. Click here to learn how to join the https://www.ademilaw.com/case/silk-road-medical-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Silk Road Medical, Inc. has obtained a Fair Price for its Public Shareholders

Silk stock skyrocketed Tuesday after Boston Scientific agreed to buy the medical devices company for $1.16 billion.

Silk Road Medicine Rockets On Boston Scientific's $1.16 Billion Takeover

Tuesday, Boston Scientific Corporation BSX agreed to acquire Silk Road Medical Inc SILK for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.

Boston Scientific Adds Stroke Prevention To Vascular Portfolio Via Silk Road Medical's $1.3B Deal

Silk Road Medical (NASDAQ: SILK ) stock is on the rise Tuesday after the medical device company announced an acquisition deal with Boston Scientific (NYSE: BSX ). This deal has Boston Scientific agreeing to acquire shares of SILK stock for $27.50 each in cash.

Why Is Silk Road Medical (SILK) Stock Up 24% Today?

SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a leading shareholder rights law firm, announced today that it has initiated an investigation into the board members of Silk Road Medical, Inc. (NASDAQ: SILK) concerning potential breaches of fiduciary duties related to the proposed sale of the Company to Boston Scientific (NYSE:BSX).

Breaking News: Is Silk Road Medical's $27.50 Per Share Sale Price a Fair Deal? Johnson Fistel, LLP Investigates Deal Terms

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Silk Road Medical, Inc. (NASDAQ: SILK) to Boston Scientific Corporation for $27.50 in cash per share is fair to Silk Road shareholders. Halper Sadeh encourages Silk Road shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns.

SILK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Silk Road Medical, Inc. Is Fair to Shareholders

Boston Scientific will pay $27.50 a share, or $1.16 billion, for Silk Road Medical.

Silk Road Medical Stock Soars. It's Being Acquired by Boston Scientific.

Boston Scientific will acquire medical device maker Silk Road Medical in a $1.16 billion deal, the companies said on Tuesday.

Boston Scientific to buy Silk Road Medical in $1.16 billion deal

Silk Road Medical Inc.'s stock SILK, +1.31% was up 22.6% in pre-market trades on Tuesday after it agreed to be acquired by Boston Scientific Corp. BSX, -0.74% for $27.50 a share. The deal values the medical device company at just under $1.2 billion.

Silk Road Medical stock rallies on Boston Scientific acquisition deal

Acquisition adds innovative technology for stroke prevention to vascular portfolio MARLBOROUGH, Mass. , June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).

News for Silk Road Medical Inc Stock (SILK)